Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 36 min ago
Peer-reviewedCC BY 4.0Renal Failure

Effect of Kunxian capsule, a novel Tripterygium wilfordii preparation, on reducing proteinuria and slowing renal function decline in diabetic kidney disease: a 48–week randomized controlled trial

  1. 1Department of Nephrology, The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China
  2. 2Department of Computing, The Hong Kong Polytechnic University, Hong Kong, China

Abstract

Background: Diabetic kidney disease (DKD), a leading cause of chronic kidney disease, remains a clinical challenge despite renin–angiotensin system blockade. This study evaluated the efficacy and safety of adding Kunxian capsule to standard therapy with irbesartan in patients with DKD.

Methods: Eighty patients with DKD were randomly assigned to either the experimental group (standard therapy with irbesartan plus Kunxian capsule) or the control group (standard therapy with irbesartan) for 48 weeks. Primary outcomes included the proteinuria remission rate, degree of proteinuria reduction, and median time to remission. Secondary outcomes included the slope of eGFR decline and the incidence of renal composite hard endpoint. Safety was assessed by monitoring adverse events. This trial was registered in ClinicalTrials.gov on March 2, 2021 (No. NCT04981613).

Results: In the intention–to–treat analysis, the experimental group had a higher proteinuria remission rate (57.50% vs. 25.00%), a shorter median time to remission (5 months vs. not reached), and a greater reduction in 24–hour urinary protein than the control group. A lower incidence of renal composite hard endpoint was observed in the experimental group (10.00% vs. 32.50%), accompanied by a slower eGFR decline. No significant differences in the incidence of adverse events were observed between the two groups. Inflammatory markers, including C–reactive protein and erythrocyte sedimentation rate, were significantly reduced in the experimental group.

Conclusions: Adding Kunxian capsule to standard therapy with irbesartan improved the proteinuria remission rate and attenuated renal function decline in patients with DKD, supporting its potential as a promising adjunctive therapy.

Related

  1. Association of finerenone plus tripterygium glycosides with proteinuria reduction in patients with diabetic kidney disease: a retrospective cohort study
    Qi Gao, Yuan Cai, Yuanbo Zhang +5
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyFrontiersCrossrefDOAJ
  2. Effect of Hydroxychloroquine on Proteinuria and Inflammatory Markers in Chronic Glomerulopathy: A Proof-of-Concept Randomized Controlled Trial (HCQ-CGN Trial)
    Thitirat Supasil, Paramat Thimachai, Ouppatham Supasyndh +1
    Glomerular DiseasesPeer-reviewedCC BY 4.0Full textGeneral medicinePMC
  3. Comparison of Metronidazole Gel and Povidone‑Iodine for Vaginal Preparation in Preventing Post‑Cesarean Infection‑Related Morbidity: A Three‑Group Randomized Controlled Trial
    Fatemeh Davodabadi, Hamideh Parsapour, Behzad Imani +2
    Health science reportsPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Effects of mindfulness-based childbirth preparation education on psychosocial outcomes in pregnancy: a randomized controlled trial.
    Sibel Ocak, Tülay Yılmaz
    BMC pregnancy and childbirthPeer-reviewedCC BY-NC-NDFull textEpidemiology & public healthEurope PMCPMC
  5. Efficacy of chlorhexidine vaginal preparation in reducing postoperative infections during emergency cesarean deliveries for women in labor: a randomized controlled trial
    Hytham Atia, Abdelrahman Saleh, Mohamed Ibrahim +1
    BMC Pregnancy and ChildbirthPeer-reviewedCC BY-NC-ND 4.0Full textSurgery & anaesthesiaPMC
BibTeX
@article{chen2026effect,
  title = {{Effect of Kunxian capsule, a novel Tripterygium wilfordii preparation, on reducing proteinuria and slowing renal function decline in diabetic kidney disease: a 48–week randomized controlled trial}},
  author = {Shengnan Chen and Yajuan Gao and Zishen Liang and Yixue Zhang and Cui Wang and Yali Tang and Jun Zhao and Ani Wang and Yan Shen},
  journal = {Renal Failure},
  year = {2026},
  month = nov,
  doi = {10.1080/0886022x.2026.2755136},
  url = {https://doi.org/10.1080/0886022x.2026.2755136},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Effect of Kunxian capsule, a novel Tripterygium wilfordii preparation, on reducing proteinuria and slowing renal function decline in diabetic kidney disease: a 48–week randomized controlled trial
AU  - Shengnan Chen
AU  - Yajuan Gao
AU  - Zishen Liang
AU  - Yixue Zhang
AU  - Cui Wang
AU  - Yali Tang
AU  - Jun Zhao
AU  - Ani Wang
AU  - Yan Shen
PY  - 2026
DA  - 2026/11/04
JO  - Renal Failure
DO  - 10.1080/0886022x.2026.2755136
UR  - https://doi.org/10.1080/0886022x.2026.2755136
AB  - Background: Diabetic kidney disease (DKD), a leading cause of chronic kidney disease, remains a clinical challenge despite renin–angiotensin system blockade. This study evaluated the efficacy and safety of adding Kunxian capsule to standard therapy with irbesartan in patients with DKD.  Methods: Eighty patients with DKD were randomly assigned to either the experimental group (standard therapy with irbesartan plus Kunxian capsule) or the control group (standard therapy with irbesartan) for 48 weeks. Primary outcomes included the proteinuria remission rate, degree of proteinuria reduction, and median time to remission. Secondary outcomes included the slope of eGFR decline and the incidence of renal composite hard endpoint. Safety was assessed by monitoring adverse events. This trial was registered in ClinicalTrials.gov on March 2, 2021 (No. NCT04981613).  Results: In the intention–to–treat analysis, the experimental group had a higher proteinuria remission rate (57.50% vs. 25.00%), a shorter median time to remission (5 months vs. not reached), and a greater reduction in 24–hour urinary protein than the control group. A lower incidence of renal composite hard endpoint was observed in the experimental group (10.00% vs. 32.50%), accompanied by a slower eGFR decline. No significant differences in the incidence of adverse events were observed between the two groups. Inflammatory markers, including C–reactive protein and erythrocyte sedimentation rate, were significantly reduced in the experimental group.  Conclusions: Adding Kunxian capsule to standard therapy with irbesartan improved the proteinuria remission rate and attenuated renal function decline in patients with DKD, supporting its potential as a promising adjunctive therapy.
SN  - 0886-022X
SN  - 1525-6049
ER  -